Pathologic complete response and survival after neoadjuvant chemotherapy in cT1-T2/N0 HER2+ breast cancer

Women with small HER2+ breast cancers may have excellent prognosis with adjuvant single-agent chemotherapy and HER2-targeted therapy. The role of de-escalated therapy in the neoadjuvant setting, however, remains uncertain. We conducted a cohort study of adult women with T1-2/cN0 HER2+ breast cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: An, Selena J., Duchesneau, Emilie D., Strassle, Paula D., Reeder-Hayes, Katherine, Gallagher, Kristalyn K., Ollila, David W., Downs-Canner, Stephanie M., Spanheimer, Philip M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098414/
https://www.ncbi.nlm.nih.gov/pubmed/35552411
http://dx.doi.org/10.1038/s41523-022-00433-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098414/
https://www.ncbi.nlm.nih.gov/pubmed/35552411
http://dx.doi.org/10.1038/s41523-022-00433-x

Ejemplares similares